Table 2.
Clinician-reported participant characteristics
| Clinical characteristics | Overall N = 21a | Pleural N = 18 | Peritoneal N = 4 |
|---|---|---|---|
| Years since mesothelioma diagnosis | |||
| Mean (SD) | 1.2 (1.5) | 1.1 (1.5) | 1.4 (1.9) |
| Range (Min, Max) | (0.1, 4.8) | (0.1, 4.8) | (0.2, 4.2) |
| Stage of mesothelioma, n (%)b | |||
| Stage I/Stage II | 3 (14.3%) | 3 (16.7%) | 0 (0%) |
| Stage III/Stage IV | 17 (80.9%) | 14 (77.8%) | 4 (100%) |
| RECIST criteria, n (%)d | |||
| Partial response (PR) | 4 (19.0%) | 2 (11.1%) | 2 (50.0%) |
| Progressive disease (PD) | 4 (19.0%) | 4 (22.2%) | 0 (0%) |
| Stable disease (SD) | 10 (47.6%) | 9 (50.0%) | 2 (50.0%) |
| ECOG performance status grade | |||
| Grade 0: Fully active | 8 (38.1%) | 7 (38.9%) | 2 (50.0%) |
| Grade 1: Restricted, light work only | 13 (61.9%) | 11 (61.1%) | 2 (50.0%) |
| Comorbiditiesc | |||
| Asthma | 3 (14.3%) | 3 (16.7%) | 1 (25.0%) |
| Anxiety/depression | 2 (9.5%) | 1 (5.6%) | 1 (25.0%) |
| Arthritis | 2 (9.5%) | 2 (11.1%) | 0 (0%) |
| Other cancere | 10 (47.6%) | 9 (50.0%) | 1 (25.0%) |
| Diabetes | 2 (9.5%) | 2 (11.1%) | 0 (0%) |
| Hypertension (high blood pressure) | 12 (57.1%) | 12 (66.7%) | 0 (0%) |
| Chest pain/abdominal pain | 3 (14.3%) | 2 (11.1%) | 1 (25.0%) |
| Otherf | 6 (28.6%) | 5 (27.8%) | 1 (25.0%) |
| None | 1 (4.8%) | 1 (5.6%) | 0 (0%) |
| Current medicationsb | |||
| Chemotherapy or other cancer treatment | 18 (85.7%) | 16 (88.9%) | 3 (75.0%) |
| Nutritional support | 9 (42.9%) | 8 (44.4%) | 1 (25.0%) |
| Pain medications/corticosteroids | 11 (52.4%) | 9 (50.0%) | 3 (75.0%) |
| Otherg | 4 (19.0%) | 3 (16.7%) | 1 (25.0%) |
aOne patient had pleural and peritoneal disease and is included in both disease-specific columns
bOne pleural participant with “unknown” status
cNot mutually exclusive
dThree pleural participants with “unknown” RECIST criteria
eAs a requirement for study eligibility the participants had to be currently disease-free from other invasive malignancy and recovered from any toxicity related to previous or current anticancer therapies for other cancer
fFor pleural participants: one participant reported having “GERD, gastroparesis, hyperlipidemia”; one participant reported having “allergies, hyperparathyroidism, GERD”; one participant reported having “chronic kidney disease”; one participant reported Congestive heart failure/Heart disease; one participant reported “COPD.” The one peritoneal participant reported having “anemia”
gOther = Correction of metabolic syndrome disorder (n = 3; 2 pleural, 1 peritoneal). Antibiotics (n = 1 pleural)